Petrelintide
Long-acting amylin analog. Roche–Zealand partnership in 2025 brought it into front-line obesity competition.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
Zealand Pharma's long-acting amylin analog designed for once-weekly dosing. The leading mono-amylin candidate — distinct from cagrilintide, which is paired with semaglutide.
- Class
- Long-acting amylin analog
- Sponsor
- Zealand Pharma / Roche (partnership 2025)
- Stage
- Phase 2/3
- Lead use case
- Obesity (mono-therapy)
What it is
Petrelintide is a long-acting amylin receptor agonist designed for once-weekly subcutaneous dosing as a monotherapy for obesity. It belongs to the same therapeutic class as cagrilintide but is being developed as a stand-alone agent rather than as part of a combination.
Current research status
The Phase 2 program in obesity has shown placebo-adjusted weight loss in the high single digits, supporting Phase 3 advancement. The 2025 Zealand–Roche partnership brought significant resources into the program, positioning petrelintide as a front-line late-stage candidate alongside the dual and triple incretin agonists.
Mechanistic rationale
Amylin is co-secreted with insulin from pancreatic beta cells and acts on amylin receptors in the area postrema and other brainstem centers. The downstream effects — slowed gastric emptying, glucagon suppression, and central appetite reduction — overlap with but are mechanistically distinct from the GLP-1 axis.
Available evidence
Phase 2 obesity trial — Placebo-adjusted weight reduction in the 7-9% range over 28-36 weeks, with a tolerability profile that compares favorably to the GI-heavy GLP-1 class.[1]
The amylin axis has had its place established by pramlintide (Symlin, FDA-approved 2005) for adjunctive use in T1D and T2D. Cagrilintide demonstrated the long-acting amylin concept; petrelintide extends it as a monotherapy candidate.
Why it's interesting
Amylin agonism produces a different tolerability profile than GLP-1 agonism — generally less GI burden, with the appetite-suppression mechanism centered in the brainstem rather than the gut. For patients who don't tolerate GLP-1 agents well, an amylin monotherapy could be a meaningful alternative. The Roche partnership signals serious commercial interest in this hypothesis.
Limitations & risks
Mono-amylin weight loss in Phase 2 has been smaller than what GLP-1 agonists achieve at comparable timepoints. Whether petrelintide finds a place as a primary obesity therapy or as a complementary option will depend on the Phase 3 magnitude and the head-to-head positioning. The amylin-axis safety story is generally favorable from pramlintide's long history, but long-term mono-amylin dosing in healthy obese adults is not yet characterized at scale.
Community discussion notes
Less discussed than retatrutide or MariTide in biohacker communities, but tracked closely in metabolic-medicine specialty discourse. The Roche-Zealand deal in 2025 raised the molecule's profile substantially.
The takeaway
Petrelintide is the leading mono-amylin candidate in development and one of the more credible non-incretin obesity programs. Its Phase 3 magnitude and tolerability profile relative to GLP-1 agents will determine whether it carves out a meaningful clinical niche.
References
- Zealand Pharma. Petrelintide (ZP-9830) Phase 2 obesity trial results (corporate disclosure / preliminary release; full publication anticipated). https://pubmed.ncbi.nlm.nih.gov/?term=petrelintide
- Lutz TA. Roles of amylin in satiation, adiposity and brain development. Forum Nutr. 2010;63:64-74. https://pubmed.ncbi.nlm.nih.gov/19955773/